These findings are consistent with evidence that TNF antagonists can directly inhibit the osteoclast pathway in patients with PsA [23,24], and with radiographic outcomes observed in patients with RA [21,25,26]. The gene discussed is TNF; the disease is rheumatoid arthritis.